Price targets of $270 to $320

  • Insulet (PODD) stocks recently received several price target changes. These are the details.

Insulet (PODD) stocks recently received several price target changes.

Price target: Increase from $260 to $270

Evaluation: Neutral

Analyst firm: Citi

Citi analysts adjusted the rating after the third quarter results. And Citi analysts noted that if the company continues to roll out quarters like Q3 2022, the valuation envelope is likely to be expanded.

Price target: Increase from $300 to $315

Evaluation: Surpass

Analyst firm: Bayard

Baird analysts said they achieved impressive U.S. growth in the third quarter to the point that they still don’t understand how its recurring revenue stream model can falter as much as it did this quarter. And international growth has also been reasonably strong.

Price target: Dropped from $280 to $320

Evaluation: Surpass

Analyst firm: Raymond James

Analysts at Raymond James adjusted the rating while noting third-quarter results were stellar with strength where there needs to be strength as U.S. sales provided all the upside. And the results reinforce Raymond James’ belief that the Omnipod 5 (OP5) is Med Tech’s best new product cycle.

Price target: Dropped from $285 to $320

Evaluation: To buy

Analyst firm: BTIG

BTIG analysts adjusted the rating after the third quarter earnings beat and increased guidance for fiscal year 2022. And BTIG analysts believe strong demand for Omnipod 5 (OP 5) can be sustained at the in the coming quarters as the rollout continues and Insulet expands into new geographies and patient populations.

Eleanor C. William